Somatropin (synthetic human growth hormone) can now be prescribed on the NHS for two additional paediatric indications.
In addition to children with growth failure associated with growth hormone deficiency, Turner syndrome, Prader-Willi syndrome or chronic renal insufficiency, somatropin is recommended as an option for children born small for their gestational age who experience subsequent growth failure at ≥4 years and those with short stature homeobox-containing gene (SHOX) deficiency.
NICE guidance states that treatment should be initiated, monitored and discontinued by a specialist.
Discontinuation is indicated if any of the following apply:
- growth velocity increases less than 50% from baseline in the first year of treatment
- final height is approached and growth velocity is less than 2cm in 1 year
- there are insurmountable problems with adherence
- final height is reached
Further information: NICE guidance on Somatropin